JB Capital LLC Boosts Holdings in Merck & Co., Inc. $MRK

JB Capital LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 137,269 shares of the company’s stock after purchasing an additional 9,354 shares during the period. JB Capital LLC’s holdings in Merck & Co., Inc. were worth $14,449,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in MRK. DLD Asset Management LP lifted its holdings in Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after buying an additional 11,000,000 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Merck & Co., Inc. by 192.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 5,496,664 shares of the company’s stock valued at $461,335,000 after buying an additional 3,618,532 shares during the last quarter. Invesco Ltd. grew its stake in shares of Merck & Co., Inc. by 16.6% during the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock valued at $1,665,585,000 after acquiring an additional 2,821,766 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Merck & Co., Inc. by 20.7% during the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock valued at $1,336,877,000 after acquiring an additional 2,735,459 shares in the last quarter. Finally, Corient Private Wealth LLC increased its position in shares of Merck & Co., Inc. by 85.6% during the second quarter. Corient Private Wealth LLC now owns 4,937,948 shares of the company’s stock worth $390,896,000 after acquiring an additional 2,277,088 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $120.62 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The firm’s 50-day simple moving average is $117.72 and its 200-day simple moving average is $103.23. The firm has a market cap of $298.21 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The business had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the firm earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 46.70%.

Insider Buying and Selling

In other news, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the sale, the executive vice president directly owned 160,174 shares in the company, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Chirfi Guindo sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the sale, the chief marketing officer directly owned 80,615 shares in the company, valued at approximately $9,825,356.20. This represents a 19.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on MRK shares. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. UBS Group raised their price objective on Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Barclays assumed coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research note on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $127.13.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.